News stories about STAAR Surgical (NASDAQ:STAA) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 45.4474006468314 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
STAAR Surgical (NASDAQ:STAA) opened at $15.30 on Tuesday. STAAR Surgical has a fifty-two week low of $8.95 and a fifty-two week high of $17.60. The stock has a market capitalization of $629.81, a P/E ratio of -382.50 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.24 and a quick ratio of 1.72.
STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, November 8th. The medical instruments supplier reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $23.47 million during the quarter. STAAR Surgical had a negative return on equity of 3.34% and a negative net margin of 2.47%. analysts anticipate that STAAR Surgical will post -0.04 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on STAA shares. Benchmark increased their price objective on STAAR Surgical from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, October 20th. Canaccord Genuity increased their price objective on STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 17th. BidaskClub lowered STAAR Surgical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Finally, Zacks Investment Research lowered STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $17.67.
In other STAAR Surgical news, VP Keith Holliday sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the completion of the sale, the vice president now directly owns 45,969 shares in the company, valued at $765,383.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “STAAR Surgical (STAA) Earns Daily Media Sentiment Rating of 0.14” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/06/staar-surgical-staa-earns-daily-media-sentiment-rating-of-0-14.html.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.